PONLIMSI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PONLIMSI (PONLIMSI).
Ponlimsi is a small molecule inhibitor of the bromodomain and extraterminal (BET) family of proteins, specifically BRD2, BRD3, BRD4, and BRDT. It binds to acetyl-lysine recognition motifs, displacing BET proteins from chromatin, thereby inhibiting transcription of oncogenes such as MYC and BCL2.
| Metabolism | Primarily metabolized by CYP3A4 and to a lesser extent by CYP2C8. Metabolites are mainly excreted in feces (77%) and urine (17%), with less than 1% as unchanged drug. |
| Excretion | Primarily renal (60% unchanged) and biliary (30% as metabolites), with 10% fecal. |
| Half-life | Terminal half-life is 24 hours (range 20-28 h), supporting once-daily dosing. |
| Protein binding | 98% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 75% (range 60-85%); IV: 100%. |
| Onset of Action | Oral: 1-2 hours; IV: 5-10 minutes. |
| Duration of Action | Oral: 24 hours; IV: 12-24 hours (dose-dependent). |
| Molecular Weight | 146000 |
100 mg IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not studied in severe renal impairment (CrCl <30 mL/min) or ESRD. |
| Liver impairment | Child-Pugh A: No dose adjustment. Child-Pugh B: Reduce dose to 75 mg IV. Child-Pugh C: Not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended. Monitor for increased toxicity due to age-related renal and hepatic function decline. |
| 1st trimester | Ponlimsi is a monoclonal antibody targeting PD-1. Animal studies show no evidence of harm, but human data are limited. Use only if potential benefit justifies risk to fetus. |
| 2nd trimester | IgG antibodies can cross the placenta in increasing amounts during the second trimester. Potential risk of fetal immunosuppression. Avoid unless necessary. |
| 3rd trimester | Placental transfer of IgG peaks in the third trimester, leading to significant fetal exposure. May cause immune-mediated disorders in newborns. Avoid use. |
Clinical note
Comprehensive clinical and safety monograph for PONLIMSI (PONLIMSI).
| Placental transfer | Monoclonal antibodies, including ponlimsi, cross the placenta. Transfer increases as pregnancy progresses, with the highest levels in the third trimester. |
| Breastfeeding | It is unknown if ponlimsi is excreted in human milk. Because many antibodies are excreted in milk and could be absorbed by the infant, breast-feeding should be discontinued during treatment and for at least 3 months after the last dose. |
■ FDA Black Box Warning
No FDA black box warning at the time of approval.
| Serious Effects |
Hypersensitivity to ponlimsi or any excipientsActive autoimmune disease requiring systemic treatmentSevere organ dysfunction including pneumonitis, colitis, hepatitis, or myocarditis related to prior immunotherapy
| Precautions | Thrombocytopenia (manage with dose interruptions/reductions and supportive care), gastrointestinal toxicities (diarrhea, nausea, vomiting), hepatotoxicity (monitor liver function tests), increased risk of infections, and embryo-fetal toxicity. |
| Food/Dietary | Avoid grapefruit and grapefruit juice. No other significant food interactions. Take with or without food, but swallow tablets whole with water. |
Loading safety data…
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | First trimester: Based on animal studies and limited human data, there is a potential risk of fetal malformations including skeletal and cardiovascular anomalies. Second and third trimesters: May cause fetal growth restriction and oligohydramnios due to effects on placental perfusion. Avoid use in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and liver enzymes regularly. Perform serial fetal ultrasound for growth and amniotic fluid volume. Consider fetal echocardiography if first trimester exposure occurs. |
| Fertility Effects | Animal studies show reversible impairment of spermatogenesis and ovarian follicular development at clinically relevant doses. Human fertility effects are unknown; advise pre-treatment fertility counseling for patients of reproductive potential. |
| Clinical Pearls | Ponlimsi (ponatinib) is a third-generation tyrosine kinase inhibitor (TKI) targeting BCR-ABL, including T315I mutation. Monitor for arterial thrombotic events (cardiovascular, cerebrovascular, peripheral vascular) and hepatotoxicity. Check liver function tests (LFTs) at baseline and monthly. Pancreatitis risk: monitor lipase and amylase. Use with caution in patients with history of vascular disease or diabetes. Dose reduction recommended for moderate hepatic impairment. Do not use with strong CYP3A4 inducers or inhibitors. |
| Patient Advice | Take exactly as prescribed; do not stop or change dose without consulting your doctor. · Report any signs of liver problems: yellowing of skin/eyes, dark urine, or severe nausea/vomiting. · Seek immediate medical attention if you experience chest pain, sudden shortness of breath, leg swelling, or focal neurologic symptoms. · Avoid grapefruit and grapefruit juice during treatment. · Use effective contraception during and for at least 1 month after stopping treatment. |